Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma Clinical Trial

Official title:

A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02728531
• Other study ID #: 201603149
• Status: Completed
• Phase: Phase 1
• Start date: April 18, 2016
• Est. completion date: August 16, 2023

Study information

• Verified date: October 2023
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Given the established role of high dose cytarabine (HiDAC) combined with rituximab, along with recent data showing the encouraging efficacy of bendamustine, the investigators seek to integrate the synergistic effects of these medicines in alternating cycles as induction therapy prior to autologous stem cell transplant (ASCT). Based on prior experience with bendamustine and rituximab (BR) based induction therapy, the investigators seek to evaluate the efficacy and safety of stem cell mobilization in this pilot study

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: August 16, 2023
• Est. primary completion date: January 16, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed mantle cell lymphoma with documented expression of CD20 (or CD 19) and cyclin D1 (BCL1) by immunohistochemical stains and/or t (11; 14) by cytogenetics or FISH

• Eighteen to 65 years of age, inclusive.

• Presence of evaluable disease by PET imaging per the Lugano classification (Cheson 201418)

• Eligible for autologous stem cell transplantation.

• ECOG performance status = 2

• Normal bone marrow and organ function as defined below:

• Absolute neutrophil count = 1,000/mcl unless in the opinion of the treating physician, neutropenia is due to splenomegaly or bone marrow involvement

• Platelets = 100,000/mcl unless in the opinion of the treating physician, thrombocytopenia is due to splenomegaly or bone marrow involvement

• Total bilirubin = 2 x IULN and AST(SGOT)/ALT(SGPT) = 3.0 x IULN except when, in the opinion of the treating physician, is due to direct involvement of lymphoma (e.g., hepatic infiltration or biliary obstruction due to lymphoma) or Gilbert's disease

• Creatinine = IULN OR creatinine clearance = 40 mL/min/1.73 m2 for patients with creatinine levels above institutional normal

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.

• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

• Negative HIV serology.

Exclusion Criteria:

• Any previous chemotherapy or radiation for mantle cell lymphoma. Short course of steroids for symptom relief prior to presentation is permissible.

• Symptomatic meningeal or parenchymal brain lymphoma.

• A history of allergic reactions attributed to compounds of similar chemical or biologic composition to rituximab, cytarabine, bendamustine or other agents used in the study.

• Severe concurrent illness, which would limit compliance with study requirements.

• Subjects with serologic status reflecting active viral hepatitis B or C infection are not eligible. Subjects whoare hepatitis B core antibody positive but antigen negative will need negative polymerase chain reaction (PCR) prior to enrollment. Hepatitis B surface antigen positive or PCR positive patients will be excluded. Subjects who are hepatitis C antibody positive will need negative PCR prior to enrollment. Patients with positive hepatitis C will be excluded.

• Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of study entry.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Mantle-Cell
• Mantle Cell Lymphoma

Intervention

Drug:
• Bendamustine

• Rituximab

• Cytarabine

• Pegfilgrastim

Procedure:
• Leukapheresis

Drug:
• Filgrastim

Procedure:
• Autologous stem cell transplant

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stem cell mobilization success rate	-Stem cell mobilization success is defined as a yield of = 2 x 106 CD34+ stem cells/kg with a maximum of 5 courses of apheresis.	Completion of stem cell mobilization (approximately 25 weeks)
Secondary	Overall response rate	-Response to treatment is guided based upon the Recommendations for Initial Evaluation, Staging and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification.	Completion of treatment (approximately 24 weeks)
Secondary	Pre-transplant complete response rate (CRR)	CRR=; Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.; London Deauville score of 1 and 2 in lymph nodes and extra lymphatic sites is considered to represent complete metabolic response. A London Deauville score 3 in the post treatment PET scan may be considered to represent complete metabolic response especially if it is not higher than the surrounding normal physiologic uptake.; No evidence of FDG avid disease in the bone marrow; No new lesions; If the bone marrow was involved by lymphoma before treatment, the infiltrate must have cleared on repeat bone marrow biopsy.	Completion of treatment (approximately 24 weeks)
Secondary	Progression-free survival (PFS)	-PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.	5 years
Secondary	Overall survival (OS)		5 years
Secondary	Safety and tolerability of bendamustine and rituximab alternating with cytarabine and rituximab as measured by grades 3 or higher toxicities	The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.	30 days following completion of treatment (approximately 29 weeks)

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine